Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
T Cell and Immune Checkpoint in Cancer
share announcement

T Cell and Immune Checkpoint in Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (15 January 2023) | Viewed by 4239

Special Issue Editors

Dr. Zohreh Amoozgar

E-Mail Website
Guest Editor
Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Interests: cancer therapy; immune checkpoint; immunotherapy; immune suppression
Special Issues, Collections and Topics in MDPI journals
Dr. Rong En Tay

E-Mail Website
Guest Editor
1. Singapore Immunology Network, Agency for Science, Technology, and Research (A*STAR), Singapore 138648, Singapore
2. Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA
Interests: cancer immunotherapy; immune checkpoint; tumor cell; T cell
Dr. Rana Jahanban-Esfahlan

E-Mail Website
Guest Editor
Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
Interests: drug delivery; cancer biology; cancer modeling

Special Issue Information

Dear Colleagues,

Immunotherapy, specifically immune checkpoint blockers (ICBs), has revolutionized the way that we treat cancer and, along with surgery, chemotherapy, and radiotherapy, it has recently formed the fourth pillar of cancer care. ICB therapy had significant benefits for patients with peripheral tumors, but this outcome did not translate to all patients and CNS tumors. Moreover, inherent and acquired resistance to ICB is an important issue that is currently being investigated in preclinical and clinical settings. The durability of response and drivers of resistance versus response is another important issue that has recently been raised within the scientific community. Our Special Issue aims to gather a comprehensive set of reviews to inform our readership, which focus on the following topics:

  • Appropriate preclinical models that have informed the trials and discussions on model selections and their consequences;
  • The responses of predictors and biomarkers to ICB therapy;
  • Combinatorial therapies that potentiate ICB;
  • Causes and consequences of the inherent and acquired resistance to ICB;
  • Therapeutic modalities and technologies that can address resistance to ICB;
  • The drivers of durable responses after ICB therapy.

Dr. Zohreh Amoozgar
Dr. Rong En Tay
Dr. Rana Jahanban-Esfahlan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • immune checkpoint blockers (ICBs)
  • ICB therapy
  • chemotherapy
  • radiotherapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 1327 KiB  
Article
FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer
by Peter Grell, Simona Borilova, Pavel Fabian, Iveta Selingerova, David Novak, Petr Muller, Igor Kiss and Rostislav Vyzula
Cancers 2023, 15(6), 1901; https://doi.org/10.3390/cancers15061901 - 22 Mar 2023
Cited by 1 | Viewed by 1918
Abstract
Immune checkpoint inhibitors (ICI) are the main therapy currently used in advanced malignant melanoma (MM) and non-small cell lung cancer (NSCLC). Despite the wide variety of uses, the possibility of predicting ICI efficacy in these tumor types is scarce. The aim of our [...] Read more.
Immune checkpoint inhibitors (ICI) are the main therapy currently used in advanced malignant melanoma (MM) and non-small cell lung cancer (NSCLC). Despite the wide variety of uses, the possibility of predicting ICI efficacy in these tumor types is scarce. The aim of our study was to find new predictive biomarkers for ICI treatment. We analyzed, by immunohistochemistry, various cell subsets, including CD3+, CD8+, CD68+, CD20+, and FoxP3+ cells, and molecules such as LAG-3, IDO1, and TGFβ. Comprehensive genomic profiles were analyzed. We evaluated 46 patients with advanced MM (31) and NSCLC (15) treated with ICI monotherapy. When analyzing the malignant melanoma group, shorter median progression-free survival (PFS) was found in tumors positive for nuclear FoxP3 in tumor-infiltrating lymphocytes (TILs) (p = 0.048, HR 3.04) and for CD68 expression (p = 0.034, HR 3.2). Longer PFS was achieved in patients with tumors with PD-L1 TPS ≥ 1 (p = 0.005, HR 0.26). In the NSCLC group, only FoxP3 positivity was associated with shorter PFS and OS. We found that FoxP3 negativity was linked with a better response to ICI in both histological groups. Full article
(This article belongs to the Special Issue T Cell and Immune Checkpoint in Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

14 pages, 948 KiB  
Review
Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence
by Jianpei Zheng, Xueyuan Zhou, Yajuan Fu and Qi Chen
Cancers 2023, 15(4), 1314; https://doi.org/10.3390/cancers15041314 - 18 Feb 2023
Cited by 2 | Viewed by 1917
Abstract
Immune checkpoint inhibitors (ICIs) including PD-1/PD-L1 antibodies, have demonstrated significant clinical benefits in the treatment of individuals with many types of cancer. However, as more and more patients use such therapies, the side effects of immune checkpoint inhibitors have also been discovered. These [...] Read more.
Immune checkpoint inhibitors (ICIs) including PD-1/PD-L1 antibodies, have demonstrated significant clinical benefits in the treatment of individuals with many types of cancer. However, as more and more patients use such therapies, the side effects of immune checkpoint inhibitors have also been discovered. These include accelerated tumor growth in some patients, creating new lesions, and even life-threatening ones. These side effects are known as hyperprogression disease (HPD), and different types of tumors have different HPD conditions after ICIs treatment. Therefore, understanding the pathogenesis of HPD and predicting its occurrence is critical for patients using ICIs therapy. Here, we will briefly review the current status of PD-1/PD-L1 antibody therapy, HPD occurrence in various types of tumors, and the underlying mechanism. Full article
(This article belongs to the Special Issue T Cell and Immune Checkpoint in Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop